

Status: Currently Official on 17-Feb-2025
 Official Date: Official as of 01-Aug-2022
 Document Type: USP Monographs
 DocId: GUID-DC3104E1-19DF-4EDC-9920-09FD9C0AB391_6_en-US
 DOI: https://doi.org/10.31003/USPNF_M88200_06_01
 DOI Ref: 6pgy6

© 2025 USPC
 Do not distribute

Vinblastine Sulfate for Injection

DEFINITION

Change to read:

Vinblastine Sulfate for Injection contains NLT 90.0% and NMT 110.0% of the labeled amount of vinblastine sulfate ($C_{46}H_{58}N_4O_9 \cdot H_2SO_4$).

CAUTION—Handle ▲vinblastine sulfate▲ (USP 1-Aug-2022) with great care because it is a potent cytotoxic agent.]

IDENTIFICATION

- **A.** [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197K

Sample: Use material previously dried in a vacuum at 60° for 16 h.

Acceptance criteria: Meets the requirements of 197K

- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

- **C.** [IDENTIFICATION TESTS—GENERAL \(191\)](#), [Chemical Identification Tests, Sulfate](#)

Sample solution: 100 mg/mL in [water](#)

Acceptance criteria: Meets the requirements

ASSAY

PROCEDURE

Solution A: [Diethylamine](#) and [water](#) (14:986). Adjust with [phosphoric acid](#) to a pH of 7.5.

Solution B: [Acetonitrile](#) and [methanol](#) (20:80)

Mobile phase: *Solution A* and *Solution B* (38:62)

Standard solution: 0.4 mg/mL of [USP Vinblastine Sulfate RS](#) in [water](#)

System suitability solution: 0.4 mg/mL of [USP Vincristine Sulfate RS](#) in *Standard solution*. [NOTE—No loss on drying determination is needed for [USP Vincristine Sulfate RS](#).]

Sample stock solution: Pipet a suitable volume of [water](#) into each of five containers of Vinblastine Sulfate for Injection to obtain a solution in each having a nominal concentration of 1 mg/mL of vinblastine sulfate. Insert the stopper, shake to mix, and combine the solutions from the five containers.

Sample solution: Nominally equivalent to 0.4 mg/mL of vinblastine sulfate in [water](#), from the *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 262 nm

Columns

Precolumn: Packed with porous silica gel; installed between the pump and the injector

Analytical: 4.6-mm × 15-cm; 5-μm packing [L1](#)

Flow rate: 2 mL/min

Injection volume: 20 μL

System suitability

Samples: *Standard solution* and *System suitability solution*

Suitability requirements

Resolution: NLT 4.0 between vincristine and vinblastine, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of vinblastine sulfate ($C_{46}H_{58}N_4O_9 \cdot H_2SO_4$) in the portion of Vinblastine Sulfate for Injection taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of vinblastine from the *Sample solution*

r_S = peak response of vinblastine from the *Standard solution*

C_S = concentration of [USP Vinblastine Sulfate RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of vinblastine sulfate in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

Change to read:

PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): ▲Meets the requirements▲ (USP 1-Aug-2022)

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Mobile phase, Standard solution, System suitability solution, and System suitability: Proceed as directed in the Assay.

Sample solution A: Use the *Sample solution*, prepared as directed in the Assay.

Sample solution B: 16 µg/mL of vinblastine sulfate in [water](#), from *Sample solution A*

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 262 nm

Columns

Precolumn: Packed with porous silica gel; installed between the pump and the injector

Analytical: 4.6-mm × 15-cm; 5-µm packing [L1](#)

Flow rate: 2 mL/min

Injection volume: 200 µL (20 µL for *System suitability*)

Analysis

Samples: *Sample solution A* and *Sample solution B*

Calculate the percentage of each ▲individual▲ (USP 1-Aug-2022) impurity in the portion of Vinblastine Sulfate for Injection taken:

$$\text{Result} = [r_{UA}/(\sum r_{UA} + 25r_{UB})] \times 100$$

r_{UA} = peak response of each ▲individual▲ (USP 1-Aug-2022) impurity appearing after the solvent peak from *Sample solution A*

r_{UB} = peak response of vinblastine from *Sample solution B*

Calculate the percentage of total impurities:

$$\text{Result} = [\sum r_{UA}/(\sum r_{UA} + 25r_{UB})] \times 100$$

r_{UA} = peak response of each ▲individual▲ (USP 1-Aug-2022) impurity appearing after the solvent peak from *Sample solution A*

r_{UB} = peak response of vinblastine from *Sample solution B*

Acceptance criteria

Individual impurities: NMT 2.0%

Total impurities: NMT 5.0%

SPECIFIC TESTS

Change to read:

- [BACTERIAL ENDOTOXINS TEST \(85\)](#): ▲Meets the requirements▲ (USP 1-Aug-2022)
- [STERILITY TESTS \(71\)](#): Meets the requirements
- [INJECTIONS AND IMPLANTED DRUG PRODUCTS \(1\)](#), [Product Quality Tests Common to Parenteral Dosage Forms, Specific Tests, Completeness and Clarity of Solutions](#): At the time of use, it meets the requirements.

- **OTHER REQUIREMENTS:** It meets the requirements for [Labeling \(7\), Labels and Labeling for Injectable Products](#).

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve as described in [Packaging and Storage Requirements \(659\), Injection Packaging, Packaging for Constitution](#), and store in a refrigerator.

Change to read:

- **LABELING:** ▲Label to indicate: ▲ (USP 1-Aug-2022) “For Intravenous Use Only—Fatal If Given By Other Routes.” When dispensed, the container ▲▲ (USP 1-Aug-2022) (holding the individual dose prepared for administration to the patient) must ▲bear▲ (USP 1-Aug-2022) the statement: “▲▲ (USP 1-Aug-2022) For Intravenous Use Only—Fatal If Given By Other Routes.”

- **USP REFERENCE STANDARDS (11).**

[USP Vinblastine Sulfate RS](#)

[USP Vincristine Sulfate RS](#)

[NOTE—No loss on drying determination is needed for [USP Vincristine Sulfate RS](#).]

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
VINBLASTINE SULFATE FOR INJECTION	Documentary Standards Support	SM32020 Small Molecules 3
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 47(2)

Current DocID: [GUID-DC3104E1-19DF-4EDC-9920-09FD9C0AB391_6_en-US](#)

DOI: https://doi.org/10.31003/USPNF_M88200_06_01

DOI ref: [6pgy6](#)

